(Q40448475)

20 September 2017

c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. (English)

1 reference

20 September 2017

Shibani Mukherjee

1

1 reference

PubMed ID

15757889

20 September 2017

Susan E Conrad

series ordinal

2

1 reference

PubMed ID

15757889

20 September 2017

language of work or name

English

0 references

publication date

8 March 2005

1 reference

Journal of Biological Chemistry

20 September 2017

1 reference

20 September 2017

280

1 reference

20 September 2017

17617-17625

1 reference

20 September 2017

18

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

20 September 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Mode of estrogen action on cell proliferation in CAMA-1 cells: II. Sensitivity of G1 phase population

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

G1 phase progression: cycling on cue

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Principles of CDK regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Inhibitors of mammalian G1 cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Molecular determinants for the tissue specificity of SERMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Making decisions through Myc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Identification of CDK4 as a target of c-MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

A human cell line from a pleural effusion derived from a breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

A versatile synthetic dimerizer for the regulation of protein-protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Functional analysis of the AUG- and CUG-initiated forms of the c-Myc protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

D-type cyclin-dependent kinase activity in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

The cyclin-dependent kinase inhibitor p21WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Cyclin A is required in S phase in normal epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

A low abundance pool of nascent p21WAF1/Cip1 is targeted by estrogen to activate cyclin E*Cdk2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

Myc suppression of the p21 Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M502278200

21 January 2018

Identifiers

DOI

10.1074/JBC.M502278200

1 reference

20 September 2017

1 reference

PubMed ID

15757889